Chemotherapy-induced alopecia is a major source of psychological stress in patients undergoing cancer chemotherapy, and it can influence treatment decisions. Although there is currently no therapy for alopecia, a fusion protein of parathyroid hormone and collagen binding domain (PTH-CBD) has shown promise in animal models. The aim of this study was to determine whether there are dose-dependent effects of PTH-CBD on chemotherapyinduced alopecia in a mouse model. C57BL/6J mice were waxed to synchronize hair follicles; treated on day 7 with vehicle or PTH-CBD (100, 320, and 1000 mcg/kg subcutaneous injection); and treated on day 9 with vehicle or cyclophosphamide (150 mg/kg intraperitoneally). Mice were photographed every 3-4 days and killed on day 63 for histological analysis. Photographs were quantified by gray scale analysis to assess hair content. Mice not receiving chemotherapy showed regrowth of hair 2 weeks after waxing and normal histology after 2 months. Mice receiving chemotherapy alone showed marked hair loss after chemotherapy, which was sustained for 10 days and was followed by rapid regrowth of a normal coat. Histological analysis revealed rapid cycling dystrophic anagen/catagen follicles. Animals receiving chemotherapy and PTH-CBD showed decreased hair loss and more rapid regrowth of hair than that seen with chemotherapy alone (increased hair growth by gray scale analysis, P < 0.05), and the effects were dose dependent. Histologically, hair follicles in animals receiving the highest dose of PTH-CBD were in a quiescent phase, similar to that in mice that did not receive chemotherapy. Single-dose subcutaneous administration of PTH-CBD showed dose-dependent effects in minimizing hair loss and speeding up recovery from chemotherapy-induced alopecia.
Introduction
Chemotherapy-induced alopecia is an emotionally distressing side-effect of cancer chemotherapy [1] . Most chemotherapeutic agents cause alopecia, which can be severe [2] . More than half of all people diagnosed with cancer receive chemotherapy, and B65% of them develop chemotherapy-induced alopecia [3] . Alopecia as a sideeffect can cause severe enough psychological distress to influence a patient's decision making and cause them to decide against potentially lifesaving chemotherapy regimens [4, 5] . Unfortunately, attempts to prevent or treat chemotherapy-induced alopecia have met with limited success [6, 7] . The most favorable results have been reported with a scalp cooling device [8, 9] , which reduces the deleterious effect of chemotherapeutic agents on hair follicles by causing hypothermia and reducing blood flow to the scalp [10, 11] . The actual results can vary between patients and chemotherapy regimens [12] , and there is a concern that scalp hypothermia may interfere with the antitumor effects of the chemotherapeutics in the scalp, increasing the risk of scalp metastasis [13] [14] [15] .
Parathyroid hormone (PTH) agonists and antagonists have been shown to modulate the hair follicle response to chemotherapy-induced damage in depilated mice, resulting in improved hair growth effects following chemotherapy [16] . To improve delivery and retention of PTH to the skin, we synthesized a fusion protein linking the agonist PTH (1-33) to a collagen binding domain (CBD) derived from ColH collagenase of Clostridium histolyticum [17] . We previously reported that this compound, PTH-CBD, had greater effects on hair regrowth in the depilated mouse model of chemotherapy than that seen with a similarly linked PTH antagonist [18] . We also showed beneficial effects of PTH-CBD on chemotherapy-induced alopecia in a more clinically relevant model of cyclic administration of chemotherapy in the absence of waxing [19] . We now report dose responsiveness of this effect to provide dose optimization and further verification of the efficacy of the compound.
Methods

Animals
Forty-two female C57BL/6J mice aged 3-5 weeks were obtained from the Jackson Laboratory (Bar Harbor, Maine, USA). They were then acclimatized for 2 weeks in the animal room and exposed to a 12/12 h light/dark period at a temperature of 68-701C. The mice were given access to tap water and a diet consisting of 18% protein purchased from Harlan Company (Barton, Illinois, USA and Madison, Wisconsin, USA). Approval of the Institutional Animal Care and Use Committee for these studies was obtained from Ochsner Clinic Foundation (New Orleans, Louisiana, USA).
Chemicals
The chemotherapeutic agent cyclophosphamide was obtained from the cancer infusion center of Ochsner Clinic Foundation as a solution and was used within 24 h. The concentration of the cyclophosphamide was 20 mg/ ml. The working solution of the fusion protein, PTH-CBD, was prepared fresh and diluted in collagen binding buffer (50 mmol/l Tris HCl, 5 mmol/l CaCl 2 , pH 7.5).
Depilation
To ensure greater uniformity of response and to permit quantitative grading of the response to each dose, we utilized the depilated mouse model of chemotherapyinduced alopecia in this study. Mice were depilated by shaving followed by waxing using Sally Hansen strips (Hair Remover Wax Strip Kit -Face; Sally Hansen, New York, New York, USA) purchased from a local vendor (Wal-Mart, Luling, Lousiana, USA). Depilation was performed according to the manufacturer's instructions.
Study protocol
Forty-two mice were divided into five groups as follows:
(1) No Chemo (six mice) (2) Chemo (nine mice) (3) Chemo + PTH-CBD (100 mcg/kg; nine mice) (4) Chemo + PTH-CBD (320 mcg/kg; nine mice) (5) Chemo + PTH-CBD (1000 mcg/kg; nine mice) On day 0, the backs of the mice were shaved and then depilated by waxing to synchronize the hair follicles. On day 7, No Chemo and Chemo mice received a single subcutaneous injection of collagen binding buffer; the remaining groups received a single dose of either 100, 320, or 1000 mcg/kg of PTH-CBD through a subcutaneous injection placed caudally in the depilated region. On day 9, 150 mg/kg of cyclophosphamide was administered intraperitoneally to all animals except for the No Chemo mice. Chemotherapy administration was timed to maximize the damage to hair follicles [16] .
Photo documentation
In addition to daily observation, photographs were documented every 3-4 days to provide a record of changes in hair growth. Images were captured using the Kodak Gel Logic 100 Imaging System (Eastman Kodak Company, Rochester, New York, USA) on a Spectroline Bi-O-Vision UV/white light transilluminator (Spectronics Corporation, Westbury, New York, USA). Photographs were taken with 0.2 s exposure, 2 mm F-stop, and 15 mm magnification to keep the hair texture in the linear range for analysis. Images were evaluated qualitatively and analyzed by gray scale analysis, as previously described [19] . Briefly, light absorption within specified regions was quantified using the provided software, with greater absorption corresponding to increased hair growth. In this study, an elliptical region of interest was selected on the dorsal skin of the mouse at the site of injection. This densitometric value was normalized to the average of those obtained from two background regions of interest placed on either side of the mouse.
Histology
Mice were killed at the end of the study (day 63). Skin samples from the dorsal (middle of the back) region were obtained. The skin samples were fixed in 10% buffered formalin, and longitudinal slices were processed for routine histological analysis by hematoxylin and eosin staining.
Biochemical assays
Serum calcium levels were measured using the Quanti-Chrom Calcium Assay Kit (DICA-500; BioAssay Systems, Hayward, California, USA).
Bone mineral density measurements
Bone mineral density (BMD) of the animals was measured at 0, 2, 4, 6, and 8 weeks of the experimental period using a Hologic QDR 1000 plus DXA machine (Hologic Inc., Bedford, Massachusetts, USA) as described previously [20] .
Statistical analysis
Relative absorption from gray scale analysis was analyzed using two-way analysis of variance (ANOVA), followed by one-way ANOVA at each time point and post-hoc Tukey's test. Serum calcium level was analyzed by ANOVA. BMD was analyzed by two-way ANOVA, followed by one-way ANOVA at each time point and Dunnett's post-hoc test, as indicated for each comparison. Statistical analyses were carried out using GraphPad Prism 5.0. (GraphPad Software Inc., La Jolla, California, USA).
Results
Photo documentation
No Chemo mice showed rapid regrowth of hair during the first 2 weeks after depilation on gross observation, as expected ( Fig. 1 ). Even in mice subjected to chemotherapy alone, there was initial regrowth of hair after waxing, which reversed to near-total hair loss within 1 week after receiving chemotherapy. This hair loss persisted for B10 days and was followed by rapid regrowth of a normal hair coat. In chemotherapy animals treated with PTH-CBD, there was appreciably greater regrowth of hair within the first month after chemotherapy, particularly at the site of administration and in rough proportion to the dose of PTH-CBD administered (Fig. 1 ). In addition, as PTH-CBD was administered at a more caudal site, the normal cranial to caudal pattern of hair regrowth was reversed in treated animals. As would be predicted from the distribution studies [18] , these effects were not restricted to the site of injection, and reduced thinning and color change in the nondepilated regions was also noticeable. In all groups, there was no observable change in hair growth in regions where the hair coat is normally thin, that is, ears and tail.
Quantitative assessment of hair growth by gray scale analysis
Taking advantage of the black hair color in C57BL/6J mice, we carried out gray scale analysis on serial photographs at the site of injection, with higher absorption corresponding to increased hair growth. According to this analysis, the No Chemo group showed marked increases in light absorption during the first 2 weeks (Fig. 2) , corresponding to the time of visually apparent hair growth. As expected, this response was sustained, although there was a mild trend toward lower light absorption after day 42. The group subjected to chemotherapy alone showed a rapid decrease in light absorption by day 18, which was sustained until day 28 (21 days after chemotherapy). There was then a marked increase in light absorption, corresponding to increased visual hair growth (Fig. 2) . By day 42, light absorption did not differ between the Chemo and No Chemo groups. PTH-CBD treatment appeared to have a dose-dependent effect on increased light absorption (corresponding to increased hair growth) during this window of chemotherapy-induced hair loss.
Histology
On the basis of our previous study, we expected animals in the No Chemo group to respond to waxing with marked stimulation of anagen VI hair follicles [18] . However, as this study was continued to a later time point, at 63 days after waxing there was no evidence of such regeneration, rather hair follicles appeared to be in a quiescent state ( Fig. 3) , consistent with healing after the waxing injury. Conversely, skin samples from animals treated with cyclophosphamide (Chemo group) did show marked stimulation of anagen VI hair follicles, which may indicate a delay in the healing process after waxing. We observed melanocyte clumping around the bulb of these hair follicles, a dystrophic change that has been described previously after chemotherapy administration [21] . Of note, although there were histological differences between the Chemo and No Chemo groups, the coat of the animals was visually indistinguishable (not shown).
Skin samples from the 100 and 320 mcg/kg Chemo + PTH-CBD groups showed mixed findings, with both quiescent regions resembling those seen in the No Chemo group, and regenerating regions resembling those seen in the Chemo group (Fig. 3) . The skin samples from the Chemo + PTH-CBD group (1000 mcg/kg) showed only hair follicles in the quiescent phase ( Fig. 3) . At all doses, PTH-CBD treatment (Chemo + PTH-CBD) led to deeper rooting and reduced melanocyte clumping, thus reversing the dystrophic changes.
Bone mineral density
We have previously shown that PTH-CBD distributes to the bone and reverses chemotherapy-induced osteoporosis following a single subcutaneous injection [17] . We therefore measured the BMD in each animal at 0, 2, 4, 6, and 8 weeks of the experimental period. In the No Chemo group, we found significant increases in BMD from baseline, as would be expected in normal young mice (Fig. 4 ). This increase in BMD with age was delayed in the Chemo group, which showed lower BMD at 2, 4, and 6 weeks, but by 8 weeks had BMD similar to that of the No Chemo group. This observation is consistent with the known effect of cyclophosphamide to reduce bone formation [22, 23] , although the magnitude of the effect was lower than that seen with three courses of cyclophosphamide [17] . At the lowest dose (100 mcg/kg), PTH-CBD had no observable effect on BMD. However, at higher doses (1000 and 320 mcg/kg), PTH-CBD increased BMD to levels at or above those seen in the No Chemo group. In fact, analysis of the BMD values at 8 weeks by ANOVA followed by Dunnett's test (comparing all groups with the Chemo group) indicated that BMD values were significantly increased after administration of 1000 or 320 mcg/kg PTH-CBD, but not in the No Chemo group. Thus, higher doses of PTH-CBD did result in increases in BMD, which corrected the deficit caused by chemotherapy administration.
Serum calcium
As the above-mentioned changes in BMD showed evidence of systemic absorption of the CBD peptides, we measured serum calcium levels at the time of sacrifice (day 63). Serum calcium levels showed no statistically significant differences between the groups (Fig. 5 ).
Discussion
PTH-CBD is a fusion protein of a bacterial collagen binding domain and a PTH (1-33) agonist. This compound was designed to promote distribution and retention of the active component in collagen-containing tissues, such as skin and bone. We tested whether there were dose-dependent effects of PTH-CBD on chemotherapy-induced alopecia using a depilated mouse model. Synchronizing the hair follicles by depilation (waxing) is a commonly used model for inducing chemotherapyinduced alopecia. It has the advantage of maximizing chemotherapy-induced damage with a single course of chemotherapy, minimizing other systemic effects of the chemotherapeutics and improving survival. Importantly for this study, it provides a more uniform platform for assessing drug responses, in that the response of the animals is more consistent. Unfortunately, waxing itself causes injury to hair follicles, for which there is a persistent anagen response at 30 days in mice that do not receive chemotherapy [18] . We therefore extended this study for another month and observed that this anagen response resolves by day 63, with normal quiescent hair follicles observed on histological analysis. Thus, this extended model provides the opportunity to assess whether therapeutic agents can return the hair follicles to a truly normal state.
Taking advantage of the uniformity of this model, we compared hair growth responses visually, quantitatively by gray scale analysis, and histologically by assessing the stage and dystrophy of hair follicles. We observed that PTH-CBD had positive, dose-dependent effects in all these areas, speeding up regrowth of hair and resolving chemotherapy-induced hair follicle dystrophy [18] . These findings were confirmed by gray scale analysis, which showed that the animals treated with chemotherapy and PTH-CBD exhibited significantly greater average light absorption on the dorsum compared with those receiving chemotherapy alone, again in a dosedependent manner.
Although mice treated with cyclophosphamide alone showed a normal hair coat at the end of the study (day 63), the histological appearance was quite different from that in animals that did not receive chemotherapy. The hair follicles were still regenerating and were predominantly in the dystrophic anagen and catagen phases, whereas samples from the No Chemo group showed normal telogen hair follicles (Fig. 3 ). Animals treated with the highest dose of PTH-CBD also showed a normal hair coat; however, histological analysis showed the hair follicles to be in a quiescent phase, similar to that in animals that did not receive chemotherapy. Animals receiving a lower dose of PTH-CBD showed a mixed response on histological examination, with both regenerating and quiescent regions present on the same skin sample. These observations suggest that PTH-CBD This accelerated healing response likely resulted from an early stimulation of hair follicle regeneration by PTH-CBD; indeed, we did observe accelerated anagen responses to PTH-CBD at the 30-day time point in a previous study [18] . Activation of PTH receptors has been shown to increase production of b-catenin [24] , which in turn induces hair follicle transition to the anagen phase [25, 26] . While in this phase, the hair follicles may be more susceptible to damage from chemotherapy; however, the continued regenerative stimulus provided by PTH-CBD would result in more rapid repair of this damage, with a net positive effect on hair growth after chemotherapy.
The lack of continued anagen response 63 days after PTH-CBD dosing might suggest that the effects of the medication have worn off by this time point. This is different from more prolonged anabolic effects seen in bone 9-12 months after a single subcutaneous injection of PTH-CBD [17] and may be the result of increased metabolic activity and increased blood flow to the skin versus bone [17] . Indeed, animals in this study treated with Chemo + PTH-CBD (320 or 1000 mcg/kg) showed higher BMD than that seen in Chemo mice, and by 8 weeks the BMD was higher than that seen in all other groups, including the No Chemo group. Thus, although the effects of PTH-CBD on skin may have been waning by day 63, there was evidence of a continuing anabolic effect on bone. Of note, despite evidence of systemic absorption of PTH-CBD, there was no difference in serum calcium levels between groups at the end of the study (Fig. 5 ). It is possible that these hair growth effects at the site of administration may be prolonged and systemic absorption minimized using variations of PTH-CBD with enhanced collagen binding activity.
Overall, PTH-CBD showed dose-dependent effects in minimizing and speeding up recovery from chemotherapyinduced alopecia. This was evident on gross observation, quantification of hair growth using a novel gray scale analysis technique, and on histological examination. PTH-CBD also reversed the effects of chemotherapyinduced bone loss, indicating that there was significant systemic absorption. Future studies will investigate whether systemic effects can be minimized through topical administration and/or use of variations of PTH-CBD with enhanced collagen binding activity. Ultimately such compounds may help provide relief for cancer patients from chemotherapy-induced alopecia. Ochsner Clinic Foundation for providing support for these studies. The authors gratefully acknowledge support, in whole or in part, by the National Institutes Chemo+PTH−CBD 320
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Bone mineral density (BMD): 7-week-old female C57BL/6J mice received single subcutaneous injections of either vehicle control or PTH-CBD at the indicated doses on day 7, followed by treatment with cyclophosphamide (intraperitoneally) or vehicle control (No Chemo group) on day 9. Animals were anesthetized, and the lumbar spine BMD was measured by dual energy X-ray absorptiometry using Hologic QDR-1000plus at 0, 2, 4, 6, and 8 weeks. The analysis was carried out by the same investigator in a blinded manner. Results are expressed as mean±SD. BMD was analyzed by two-way analysis of variance (ANOVA), followed by one-way ANOVA at each time point and Dunnett's post-hoc test, as indicated for each comparison. *P < 0.05 by one-way ANOVA. 
